Semaglutide batch quality issue delays Dr Reddys supplies

Monthly Volume DeclinedBusiness Updates View source PDF Explain this filing

DRREDDY · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-5.9%Reaction day

₹1351.10

prior close

₹1332.90

announcement price

In-mkt

timing

Nifty 100market+0.4%-6.3% vs market

Pharmaceuticals peers, median of 166sector+0.9%-6.9% vs sector

On the reaction day the stock moved 6.3 pts less than Nifty 100 and 6.9 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.6

10m

-0.6

15m

+0.7

30m

+0.6

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-5.9+0.4-6.3+0.9-6.9

Next day

-7.7+1.5-9.2+1.4-9.1

-8.5+1.4-9.9+1.8-10.3

-7.8+0.8-8.6+1.4-9.2

-9.0+1.0-10.0+1.6-10.5

-9.3+0.9-10.2+1.6-10.9

-9.6+1.6-11.2+1.2-10.8

15d

-15.3+2.0-17.3-0.5-14.8

-14.2+3.4-17.6+0.8-15.0

-15.3-1.0-14.2+2.7-18.0

-11.4-5.4-6.0-0.8-10.6

UpDownMarket · Nifty 100Sector · Pharmaceuticals peers, median of 166Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Dr Reddys says some batches of semaglutide, a metabolic therapy drug, failed quality checks due to an issue with the active pharmaceutical ingredient. The company is investigating the root cause. Commercial supplies of the drug will be delayed until the issue is fixed. No impact on patient safety or existing global regulatory approvals. Management will hold a conference call today at 4:30 PM IST to discuss.

Likely market impact

Short term supply delay in a key metabolic drug could pressure near term sales until the issue is resolved.